MSB 2.17% $1.13 mesoblast limited

MSB Trading - 2019, page-4411

  1. 693 Posts.
    lightbulb Created with Sketch. 266
    Coupla things here.

    First, the trial is finished anyway, all that remains is final follow up and data verification/cleaning - thus this DMC "decision" is purely administrative and a formality that is part of the last meeting of a DMC. So be careful not to read too much into it.

    Second, the DMC will not stop a trial on efficacy grounds except in the case of overwhelming efficacy or in the event of a failed futility analysis - ie when the trial is either certain to succeed or certain to fail. When you think about it, it makes sense - why would you stop a trial when the efficacy was pretty mediocre but above the futility threshold set by the sponsor (I can tell you the sponsor wouldn't be too happy)? So again be careful not to read too much into it.
 
watchlist Created with Sketch. Add MSB (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.